NCT00089765

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Completed Phase 1 Last updated 2 July 2017

What this trial tests

Phase 1 trial testing Ranibizumab in Von Hippel-Lindau Syndrome in 5 participants. Completed in 15 August 2007.

Timeline

10 August 2004

15 August 2007

Quick facts

Lead sponsor	National Eye Institute (NEI)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	5
Start date	10 August 2004
Estimated completion	15 August 2007
Sites	1 location across United States

Drugs / interventions tested

• Ranibizumab — full drug profile →

Conditions studied

• Von Hippel-Lindau Syndrome — all drugs for Von Hippel-Lindau Syndrome →

Sponsor

National Eye Institute (NEI)

Who can join

18 and older, any sex, with Von Hippel-Lindau Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will examine whether he drug ranibizumab can slow or stop the growth of angiomas (blood vessel tumors) in patients with Von Hippel-Lindau syndrome (VHL). Angiomas commonly develop in the back of the eye on the retina and the optic nerve in patients with VHL. Although these tumors are not cancerous, they may cause significant vision loss. Current treatments, including laser therapy, cryotherapy, and vitrectomy, may not be successful or possible for all patients. Ranibizumab decreases production of VEGF, a growth factor that is important for the formation of new blood vessels and that is elevated in patients with VHL. Preliminary findings from other studies suggest that ranibizumab can reduce retinal thickening caused by vessel and tumor growth and improve vision.

Patients 18 years of age and older with retinal angiomas due to VHL in one or both eyes and central vision loss of 20/40 or worse may be eligible for this study. Participants undergo the following tests and procedures:

* Medical history, physical examination, electrocardiogram (EKG) and blood tests.
* Eye examination, including eye pressure measurement and dilation of the pupils to examine the retina.
* Fluorescein angiography to evaluate the eye's blood vessels. For this test, a yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality.
* Optical coherence tomography to measure retinal thickness. The eyes are examined through a machine that produces cross-sectional pictures of the retina. These measures are repeated during the study to determine changes, if any, in retinal thickening.
* Stereoscopic color fundus photography to examine the back of the eye. The pupils are dilated with eye drops to examine and photograph the back of the eye.
* Electroretinogram (ERG) to measure electrical responses generated from within the retina. For this test, the patient sits in a dark room for 30 minutes with his or her eyes patched. Then, a small silver disk electrode is taped to the forehead, the eye patches are removed, the surface of the eye is numbed with eye drops, and contact lenses are placed on the eyes. The patient looks inside an open white globe that emits a series of light flashes for about 20 minutes. The contact lenses sense small electrical signals generated by the retina when the light flashes.
* Ranibizumab injections to treat ocular angiomas. Ranibizumab is injected through a needle into the eye's vitreous (gel-like substance that fills the inside of the eye). Seven injections are given over a 28-week period. Before each injection, the surface of the eye is numbed with anesthetic eye drops. This is followed by injection of another anesthetic into the lower portion of the eye in the clear tissue surrounding the white of the eye. After a few minutes, the ranibizumab is injected into the vitreous. Patients receive ranibizumab injections at the first visit (during enrollment) and again at 4, 8, 12, 16, 20 and 24 weeks after the first injection. At the 28-week visit, the doctor will determine if further treatment is needed. Patients can continue to have injections every 4 weeks until 1 year of follow-up (54 weeks).

At each injection visit, participants repeat most of the tests described above to evaluate the response to treatment and return a week later for another eye examination.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease.
   Albiñana V, Gallardo-Vara E, de Rojas-P I, Recio-Poveda L, et al · · 2020 · cited 14× · PMID 32854260 · DOI 10.3390/jcm9092740
2. Neurological applications of belzutifan in von Hippel-Lindau disease.
   Zhang Y, Nguyen CC, Zhang NT, Fink NS, et al · · 2023 · cited 13× · PMID 36215167 · DOI 10.1093/neuonc/noac234
3. Genetics, Pathophysiology, and Current Challenges in Von Hippel-Lindau Disease Therapeutics.
   Gómez-Virgilio L, Velazquez-Paniagua M, Cuazozon-Ferrer L, Silva-Lucero MD, et al · · 2024 · cited 4× · PMID 39272694 · DOI 10.3390/diagnostics14171909